# FURVENT: HCP commentary report

> 30 verified statements (20 from speakers with a confirmed clinical role) from 15 commentary sources · 5 findings · updated Oct 18, 2026

## Report

- Trial: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
- NCT ID: NCT05607550
- Registry: https://clinicaltrials.gov/study/NCT05607550
- Sponsor: ArriVent BioPharma, Inc.
- Phase: Phase 3
- Status: Active, not recruiting
- Version: v1.0.0, edition 1
- Accepted: 2026-10-18
- Last checked: 2026-10-18
- Release hash: 6e44291e463f522bcf47f7c46f65b0df707284b8e74fbd1c24918d372291326c

## Counts

- HCP commentary sources screened: 20
- Sources cited by verified statements: 15
- Verified statements: 30
- From speakers with a confirmed clinical role: 20
- Findings: 5
- People found in screened sources: 13
- People identity-verified: 11
- Voices cited: 12

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

HCP commentary report on Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) (NCT05607550). Trial question: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT). Aspects: Primary endpoint: Progression Free Survival (PFS) determined by blinded independent central review (BICR) (discussed, 6 verified views); Secondary endpoints (discussed, 7 verified views); Population and setting (discussed, 3 verified views); The comparison (discussed, 7 verified views); Safety and tolerability (discussed, 5 verified views); Design and conduct (discussed, 4 verified views); Positioning among first-line alternatives and combination strategies (discussed, 9 verified views); Earlier furmonertinib evidence and dose uncertainty (discussed, 4 verified views); Access, administration and the chemotherapy-free treatment need (discussed, 2 verified views); Prospective expectations and reactions to the program update (discussed, 7 verified views). 20 sources screened, 15 cited. The sources reviewed for this edition only; not all HCPs or all public discussion.

## Open Medical Affairs question

How should statistical evidence and possible clinical usefulness be discussed without treating unquantified additional observations as confirmation?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. The endpoint update prompted different readings of clinical usefulness
- F2. Regimen choice, not only agent choice, shapes first-line positioning
- F3. Earlier activity did not resolve dose–tolerability questions
- F4. CNS evidence, administration and access remain practical differentiators
- F5. Earlier interest was anticipatory and sometimes explicitly conditional

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 6 | 7 | 3 | 5 | recorded | 3 |
| F2 | 9 | 7 | 5 | 5 | none recorded | 3 |
| F3 | 4 | 3 | 3 | 3 | none recorded | 3 |
| F4 | 5 | 3 | 3 | 3 | none recorded | 3 |
| F5 | 7 | 5 | 5 | 4 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 3 | 1 | 0 | 0 | 2 | 6 | 4 | 3 posts and articles | yes |
| F2 | 2 | 3 | 0 | 3 | 1 | 9 | 2 | 4 posts and articles, 1 podcast or video | yes |
| F3 | 0 | 1 | 0 | 0 | 3 | 4 | 0 | 3 posts and articles | yes |
| F4 | 2 | 2 | 0 | 1 | 0 | 5 | 0 | 2 posts and articles, 1 podcast or video | yes |
| F5 | 4 | 2 | 0 | 0 | 1 | 8 | 0 | 4 posts and articles, 1 podcast or video | no |

### Trial dimensions

- Primary endpoint: Progression Free Survival (PFS) determined by blinded independent central review (BICR): F1 (5 shared claims), F2 (1 shared claims)
- Secondary endpoints: F1 (2 shared claims), F2 (2 shared claims), F3 (1 shared claims), F4 (3 shared claims)
- Population and setting: F2 (1 shared claims), F5 (2 shared claims)
- The comparison: F2 (4 shared claims), F5 (3 shared claims)
- Safety and tolerability: F2 (1 shared claims), F3 (3 shared claims), F4 (2 shared claims)
- Design and conduct: F2 (1 shared claims), F5 (3 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 6 sections | Paid |
| Verified statements with short source quotes and links | 30 | Paid |
| Trial aspects mapped | 10 | Free |
| Sources with links | 15 | Counts free |
| Speaker attribution for cited voices | 12 | Paid |

## Trial aspects

10 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression Free Survival (PFS) determined by blinded independent central review (BICR) | discussed | 6 | 4 |
| Secondary endpoints | discussed | 7 | 5 |
| Population and setting | discussed | 3 | 3 |
| The comparison | discussed | 7 | 5 |
| Safety and tolerability | discussed | 5 | 4 |
| Design and conduct | discussed | 4 | 2 |
| Positioning among first-line alternatives and combination strategies | discussed | 9 | 5 |
| Earlier furmonertinib evidence and dose uncertainty | discussed | 4 | 3 |
| Access, administration and the chemotherapy-free treatment need | discussed | 2 | 2 |
| Prospective expectations and reactions to the program update | discussed | 7 | 7 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 19 | 14 |
| YouTube | 1 | 1 |

- Screened window: 2023-09-10 to 2026-10-07
- Cited window: 2023-09-10 to 2026-10-07
- Retrieved: 2026-10-18

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
- Registry: NCT05607550 (https://clinicaltrials.gov/study/NCT05607550)
- Study IDs: FURMO-004 · 2022-502977-41-00
- Sponsor: ArriVent BioPharma, Inc.
- Collaborators: Allist Pharmaceuticals, Inc.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 398 (actual)
- Start: 2023-06-01 (actual)
- Primary completion: 2025-08-15 (estimated)
- Primary endpoint: Progression Free Survival (PFS) determined by blinded independent central review (BICR) (Up to 32 months after first dose)
- Intervention: furmonertinib 240 mg oral, daily (drug)
- Intervention: furmonertinib 160 mg oral, daily (drug)
- Intervention: platinum-based chemotherapy (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
- Out of scope: 2 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
- 2 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
- Further source limits apply, so some matching discussion may be missing.
- The report describes the sources reviewed for this edition, not the distribution of HCP opinion. Repeated appearances of the same statement do not establish independent agreement.
- No full FURVENT results publication or protocol was available. The reported OS trend and response and investigator-assessed PFS observations lack effect sizes in the posts, limiting interpretation of clinical benefit.
- Earlier FAVOUR observations and second-line-plus furmonertinib data provide context but cannot establish FURVENT's first-line efficacy, dose comparison or safety.
- Matching regulatory labeling was not available for the furmonertinib doses or chemotherapy regimen. Regulatory descriptions in commentary were not independently established.
- Some contributions came from accounts or an organization rather than confirmed individual HCPs. Sharing a linked article does not establish endorsement of its statements.
- Dated descriptions of standard care, accrual hopes and anticipated data timing are not verification of current guidance or completed milestones.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-18: current edition

Last checked for new commentary 2026-10-18. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (30 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (11 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/furvent-nct05607550
- Agents: POST https://www.erudio.com/api/orders with {"report": "furvent-nct05607550", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=furvent-05607550

## Cite

Erudio Health. FURVENT (NCT05607550): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 18, 2026. https://www.erudio.com/reports/furvent-nct05607550

## Machine access

- JSON: https://www.erudio.com/reports/furvent-nct05607550.json
- Markdown: https://www.erudio.com/reports/furvent-nct05607550.md
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "furvent-05607550"}`